Insights

Gathering insights about Anta…

Similar companies to Anta

Anta Tech Stack

Anta uses 8 technology products and services including Microsoft Clarity, SAP, React, and more. Explore Anta's tech stack below.

Microsoft Clarity
Analytics
SAP
Customer Relationship Management
React
Javascript Frameworks
PushOwl
Marketing Automation
PWA
Miscellaneous
Apple Pay
Payment Processing
American Express
Payment Processing
Shop Pay
Payment Processing

Media & News

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed in.
Sep 19, 2025 | www.businesswire.com
Santander Consumer Launches Drive Together, Offering Dealers Pre-Qualified Leads from Web Traffic
DALLAS--(BUSINESS WIRE)--Santander Consumer USA Inc. (“Santander Consumer”) has launched Drive Together, a digital retail tool and expansion of Santander's Drive® offering that provides pre-qualification resources to support a broad range of customer and dealer needs. Drive Together is a subscription service for dealers that resides on car dealerships' websites, allowing dealers to generate pre-qualified leads from their web traffic. Santander's Drive® platform uses "soft" credit checks to preq.
Jul 08, 2025 | www.businesswire.com
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients The only SC induction data for an IL-23 inhibitor show statistically significant and clinically meaningful improvements across clinical and endoscopic measures versus placebo, consistent with IV induction SPRING HOUSE, Pa. , Feb. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn's and Colitis Organization (ECCO).
Feb 21, 2025 | www.prnewswire.com
Telsey Advisory Group LLC announces U.S. Equity Research alliance with Santander
NEW YORK--(BUSINESS WIRE)--Telsey Advisory Group LLC (TAG) announced today that it has entered a strategic alliance with Santander's U.S. broker-dealer subsidiary Santander U.S. Capital Markets LLC. TAG is a recognized leader in the consumer sector, with an established track record, highly regarded analysts, and a clear vision for expansion. TAG, founded in 2006 by Dana Telsey, is a leading equity research firm, with a strong institutional equity sales and agency trading platform focused on the.
Dec 16, 2024 | www.businesswire.com
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in Vienna. The post-hoc analysis from the LIBERTY-CD (Crohn's disease) and LIBERTY-UC (ulcerative colitis) studies suggest that dose escalation of CT-P13 SC following intravenous (IV) induction in patients who initially respond but subsequently lose response, showed clinical efficacy over an extended.
Oct 15, 2024 | www.businesswire.com
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company's XeriSol™ formulation technology to enable a novel once-weekly SC injec.
May 30, 2024 | www.businesswire.com
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance … The post U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedo...
Apr 18, 2024 | www.headlinesoftoday.com

Anta's Email Address Formats

Anta uses at least 1 format(s):

Anta Email Formats	Example	Percentage
FirstLast@anta.com	JohnDoe@anta.com	88%
First.Last@anta.com	John.Doe@anta.com	6%
FirstL@anta.com	JohnD@anta.com	3%
FirstLas@anta.com	JohnDoe@anta.com	3%

Frequently Asked Questions

Where is Anta's headquarters located?

Anta's main headquarters is located at 361008 China. The company has employees across 6 continents, including AsiaNorth AmericaEurope.

What is Anta's stock symbol?

Anta is a publicly traded company; the company's stock symbol is SC.

What is Anta's official website and social media links?

Anta's official website is anta.com and has social profiles on LinkedIn.

What is Anta's NAICS code?

Anta's NAICS code is 33992 - Sporting and Athletic Goods Manufacturing.

How many employees does Anta have currently?

As of February 2026, Anta has approximately 3.4K employees across 6 continents, including AsiaNorth AmericaEurope. Key team members include Ceo Assistant: P. X.Cmo: L. Z.Chief Information Officer: A. S.. Explore Anta's employee directory with LeadIQ.

What industry does Anta belong to?

Anta operates in the Sporting Goods Manufacturing industry.

What technology does Anta use?

Anta's tech stack includes Microsoft ClaritySAPReactPushOwlPWAApple PayAmerican ExpressShop Pay.

What is Anta's email format?

Anta's email format typically follows the pattern of FirstLast@anta.com. Find more Anta email formats with LeadIQ.

Anta

Q: What is Anta's official website and social media links?

Anta's official website is anta.com. Anta has social profiles on LinkedIn.

Q: How many employees does Anta have currently?

Anta has approximately 3.4K employees.

Q: What technology does Anta use?

Anta's tech stack includes HTTP/3, Preact, Power BI, VISA, Vue.js.

Sporting Goods ManufacturingChina1001-5000 Employees

ANTA was established in 1991; while ANTA Sports Products Limited, a widely recognized global sportswear company, was listed on the Main Board of HKEx in 2007 (Stock Codes: 2020 (HKD counter) and 82020 (RMB counter)). The mission of the Company is to bring the transcendent sports spirit into everyone’s life. ANTA Sports principally engages in R&D, design, manufacturing, marketing and sales of professional sports products including footwear, apparel and accessories. ANTA Sports aims to unlock the potential of both the mass and high-end sportswear markets. ANTA Sports is also the largest shareholder of Amer Sports, Inc., a global group of iconic sports and outdoor brands, including Arc’teryx, Salomon, Wilson, Peak Performance, and Atomic, whose shares are listed on the New York Stock Exchange (NYSE: AS).

Company Overview

Headquarters: 361008 China
Website: anta.com
Stock Symbol: SC
NAICS Code: 33992 - Sporting and Athletic Goods Manufacturing
Employees: 1001-5000

Media & News

Funding & Financials

$500M$1B
Anta's revenue is estimated to be in the range of $500M$1B

Funding & Financials

$500M$1B
Anta's revenue is estimated to be in the range of $500M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Anta

Sigma Design

KPMB Architects

Tobias Partners

Anta Tech Stack

Media & News

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Santander Consumer Launches Drive Together, Offering Dealers Pre-Qualified Leads from Web Traffic

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Telsey Advisory Group LLC announces U.S. Equity Research alliance with Santander

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Anta's Email Address Formats

Frequently Asked Questions

Where is Anta's headquarters located?

What is Anta's stock symbol?

What is Anta's official website and social media links?

What is Anta's NAICS code?

How many employees does Anta have currently?

What industry does Anta belong to?

What technology does Anta use?

What is Anta's email format?

Anta

Company Overview

Media & News

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Santander Consumer Launches Drive Together, Offering Dealers Pre-Qualified Leads from Web Traffic

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?